The "art" of medicine and the 'smokescreen' of the randomized trial off-label use of vascular devices

Catheterization and Cardiovascular Interventions

Volumn 72, Issue 7, 2008, Pages 998-1002

  Ansel, Gary M ^a   Jaff, Michael R ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angioplasty; Off label; Peripheral vascular disease; Regulatory; Stent

Indexed keywords

POLITEF;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ENDARTERECTOMY; GOVERNMENT REGULATION; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; KIDNEY ARTERY STENOSIS; LEG REVASCULARIZATION; MEDICAL ETHICS; PATIENT CARE; PATIENT SAFETY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; STENT; TREATMENT INDICATION; VASCULAR ACCESS DEVICE;

DEVICE APPROVAL; EQUIPMENT SAFETY; GOVERNMENT REGULATION; GUIDELINE ADHERENCE; HUMANS; LOWER EXTREMITY; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRODUCT LABELING; QUALITY OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL ARTERY OBSTRUCTION; RESEARCH DESIGN; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VASCULAR SURGICAL PROCEDURES;

EID: 60749092846     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21776     Document Type: Article

References (14)

1. IRB Information Sheets: Off-Label and Investigadonal. Use of Marketed Drugs, Biologies and Medical Devices. Use of a marketed product in this Drug Application (IND) Investigational Device Exempion (IDE). Available at: www.fda.gov/oc/ohrt/irbs/offlabel.html (accessed on July 31, 2008).
2. David Y, Hyman WA, Issues associated with off label use of medical devices. In Proceedings of Annual International Conference of IEEE Engineering in Medicine and Biology Society, 2007;3556-3558.
3. United States Food and Drug administration information sheets. http://www,fda.gov/OC/OHRT/IRBS/offlabel.html accessed 09/09/2008.
4. Buckman Co. v. Plaintiffs Legal Comm., 531 U.S. 341, 350 (2001).
5. Beck JM, Azari ED. FDA, off-label drug use, and informed consent: Debunking myths and misconceptions. Food Drug Law J 1998;53:71-104.
6. van de Ven PJ, Kaatee R, Beutler JJ, Beek FJ, Woittiez AJ, Buskens E, Koomans HA, Mali WP. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: A randomised trial. Lancet 1999;353:282-286.
7. Rocha-Singh K, Jaff MR, Ronenfield K, et al. Evaluation of the safety and effictiveness of renal artery stenting after unsuccessful balloon angioplasty - The ASPIRE-2 study. J Am Coll Cardiol 2005;46:776-783.
8. http://www.ncbi.nim.nih.gov/sites/enterz (accessed on July 28, 2008).
9. http:www.coralclinicaltrial.org (accessed on July 28, 2008).
10. Bridges J, Maisel WH. Malfunctions and adverse events associated with off-label use of biliary stent in the peripheral vasculature. Am J Ther 2008;15:12-18.
11. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 1999:159:2041-2050.
12. Regensteiner JO, Meyer TJ, Krupski WC, et al. Hospital vs. home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology 1997;48:291-300.
13. Rocha-Singh KJ, Jaff MR, Crabtree TR, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv 2007;69:920-92l.
14. Maisel WH. Semper fidelis: Consumer protection for patients with implanted medical devices, N Engl J Med 2008;358:985-987.